Us Fda Approves Xeris Biopharmas Recorlev To Treat Endogenous Hypercortisolemia In Patients With Cushings Syndrome

Xeris Biopharma Holdings, Inc., A Biopharmaceutical Company, Announced The Us Food And Drug Administration (Fda) Approval Of Recorlev (Levoketoconazole) For The Treatment Of Endogenous Hypercortisolemia In Adult Patients With Cushing